Jeuveau (Prabotulinumtoxin-A)

In short: Jeuveau is a product of prabotulinumtoxin-A manufactured by Daewoong Pharmaceutical, marketed by Evolus. It is a botulinum toxin type A neurotoxin injection that was approved by the FDA in 2019 for cosmetic indication (glabellar lines), has a dose equivalent to Botox, has a rapid onset of action (2-3 days) and is positioned with its economical pricing.

Description and Brand History

Jeuveau (brand name; generic name: prabotulinumtoxin-A), Evolus Inc. Botulinum toxin is a type A neurotoxin produced by Daewoong Pharmaceutical (South Korea), marketed by (American aesthetic pharmaceutical company). Development of Jeuveau was initiated by Daewoong in South Korea during the 1990s and 2000s, with the product sold under the name "Nabota" in the Korean market since the early 2000s. In 2015, Evolus Inc. (then known as Anterogen Co., Ltd.) acquired the global marketing rights to the prabotulinumtoxin-A formulation. In May 2019, the FDA approved Jeuveau for a cosmetic indication (moderate-to-severe glabellar lines).

Jeuveau's core marketing positioning is expressed by the slogan "Newtox" — a cosmetic-focused, patient-centric, and affordable price strategy. This positioning targets younger, cosmetic-first patients in a market dominated by Botox (Allergan, now AbbVie) and Dysport (Ipsen). FDA approval makes Jeuveau the first and only “cosmetic-only” type of botulinum toxin; Unlike Botox and Dysport, it is not FDA approved for medical indications (migraine, excessive sweating, cervical dystonia).

Active Ingredient and Formulation

Active Ingredient: Prabotulinumtoxin-A is the "wild-type" or "native" form of Botulinum toxin A (BoNT/A-1). Molecularly, it has a cytotoxic effect on SNAP-25 (synaptosome-associated protein of 25 kDa), one of the SNARE complex proteins, and blocks the release of acetylcholine.

Accessory Proteins: Jeuveau, like Botox and Dysport, contains the BoNT/A protein in complex form. This complex consists of 150 kDa botulinum toxin heavy chain (HC) and light chain (LC), and complex-stabilizing accessory proteins (complex proteins, nurturing factors). Similar to Jeuveau, Botox and Dysport, it contains accessory proteins; This is different from the "naked toxin" formulation of Xeomin. The presence of accessory proteins may affect the immunogenicity profile — it may have more immunogenic potential than Xeomin.

Formulation and Stabilization: Jeuveau is in lyophilized (powder) form. Like Botox, it is offered in a 100U/vial or 50U/vial vial. In its stable state, it has a shelf life of 36 months at room temperature (2-8°C refrigeration). After reconstitution, reconstitute with sterile saline; Although the standard protocol is 2.5 mL saline / 100U Jeuveau (40U/mL concentration), a more concentrated (20U/mL) or more dilute (50U/mL) preparation can be made depending on the clinician's preference.

Event Measure — Unit Definition: Jeuveau unit, like Botox and Dysport, is on a biological potency basis. Each Jeuveau unit is experimentally standardized (LD50 mouse assay or equivalent method). Clinical consensus and most head-to-head studies indicate that 1 Jeuveau Unit = 1 Botox Unit equivalent (1:1 unit equivalence); This is different from Dysport (1 Botox = 2.5-3 Dysport) allowing for ease of dosing.

Mechanism of Effect

Neuromuscular Blockade: Jeuveau (prabotulinumtoxin-A) works with an identical mechanism to Botox and Dysport. At neuromuscular junctions, botulinum toxin light chain (LC) cleaves SNAP-25, one of the SNARE complex proteins, and prevents acetylcholine (ACh) vesicles from fusing into the synapse. As a result, acetylcholine is not released into the synaptic gap, it does not bind to nicotinic ACh receptors, there is no muscle depolarization and muscle contraction is blocked.

Beginning and Progression: Following Jeuveau injection, the toxin diffuses into the target muscle and reaches the neuromuscular junction within 24-48 hours. From the clinician and patient perspective, the effect begins within 2-3 days, with progressively increasing relaxation observed within 1-2 weeks. Maximal effect, 2-3. It appears at the end of the week. This timeline is similar to Dysport (rapid onset); Botox usually starts within 4-7 days.

Duration of Effect and Reversibility: Jeuveau's motor block effect lasts for 3-4 months (similar to Botox: 3-6 months, average 4 months). After the effect begins to fade, nerve endings regenerate with new SNARE protein synthesis, acetylcholine release normalizes, and muscle activity returns. This reversibility ensures the transient and safety of BoNT/A injections.

Diffusion Profile: The diffusion characteristic of Jeuveau shows moderate-level diffusion, similar to Dysport. Botox is known for its tight localization and "narrow diffusion"; Dysport, on the other hand, exhibits a "broader diffusion" profile. Jeuveau is in between – adequate localization (maximal effect in the desired muscle) combined with minimal off-target diffusion (minimizing the risk of complications). This feature gives the clinician the advantage of practicing more "forgiving".

Indications

FDA Approved Indications: Jeuveau is approved by the FDA for only one indication:

• Moderate-Severe Glabellar Lines (Glabellar Rhytides): Dynamic and/or static lines, by intramuscular injection in adults 18+ years of age. FDA approval (May 2019) is defined as moderate to severe glabellar line depth, baseline appearance at rest and animation with 50% improvement compared to baseline at 4 weeks post-injection.

Cosmetics-Only Positioning: Unlike Botox and Dysport, Jeuveau is not FDA approved for medical indications (migraine, excessive sweating, cervical dystonia, blepharospasm, strabismus). This is Evolus' strategic marketing decision to position its cosmetic-focused product. However, clinicians also apply Jeuveau for medical indications through off-label use (particularly off-label is not prohibited); Most of them prefer Botox or Dysport in these indications.

Other Potential Uses (Off-Label): Due to its "Newtox" chemistry, Jeuveau can theoretically be used in off-label indications similar to Botox/Dysport:

• Crow's feet (lateral cantal lines)
• Forehead lines (frontal lines)
• Masseter hypertrophy (V-line contouring)
• Bunny lines (nose synonyms)
• lip flip
• Gummy smile (excessive gum display)
• Hyperhidrosis (excessive sweating) — applied clinically from a body perspective, although not exclusively glabellar approval.

However, these uses are off-label with Jeuveau's FDA and similar use of botulinum toxin (Botox, Dysport) requires independent evidence and clinician experience.

Dosing and Administration Protocol

Unit Equivalence: Jeuveau dose calculations are based on 1:1 parity to Botox. For example, if a patient finds Botox 20 Units effective in the glabellar region, the same patient is expected to get similar results with Jeuveau 20 Units. This is different from Dysport (1 Botox = 2.5-3 Dysport) or Daxxify (1 Botox = 1 Daxxify, but longer effect).

Reconstitution (Dilution): The Jeuveau 100U vial is reconstituted with sterile saline. Standard dose:

• 100U Jeuveau + 2.5 mL sterile saline = 40U/mL concentration (most clinicians prefer)
• Alternative: 100U + 2 mL = 50U/mL (more concentrated, less volume)
• Alternative: 100U + 4 mL = 25U/mL (more dilute, more volume — for spreading)

After reconstitution, mix by gently rotating the vial (never shake — protein structure may be damaged). The prepared solution is considered stable for 24 hours at 2-8°C refrigeration.

Injection Technique — Glabellar: Jeuveau glabellar injection follows the Botox/Dysport standard protocol:

1. Preparation: The application area is cleaned with antiseptic (alcohol, chlorhexidine). At-rest and full animation (frowning) photographs are taken for documentation.
2. Injection Points (5-Point Glabellar Protocol):
   • 1. Midline glabellar region (1 cm superior supraorbital notch): 4-5U
   • 2. Left medial corrugator: 8-12U
   • 3. Right medial corrugator: 8-12U
   • 4. Left lateral glabellar/procerus: 2-4U
   • 5. Right lateral glabellar/procerus: 2-4U
   • Total dose: 20-40U (Dosage range similar to Botox/Dysport)
3. Needle and Volume: 30-32 G needle, 0.1-0.2 mL per injection (intramuscular). Superficial injection increases the risk of ptosis; Too deep injection may reduce the effect.
4. Skin Reactivity: Minor hemostasis (stopping bleeding) is achieved by gently pressing the injection site.

Male and Female Dosage Difference: While men may generally need 40-50U Jeuveau due to more intense corrugator musculature; For women, a more moderate dose of 20-30U can provide effective results while preserving the natural brow position.

Titration and Follow-Up: After the first Jeuveau injection, wait 2 weeks (maximal effect). If unsatisfactory results are observed, touch-up injection can be performed after 2-4 weeks. Typical retreatment interval is 3-4 months (when the effect begins to fade).

Comparison of Botulinum Toxin Types

Comparison of Jeuveau with other types of botulinum toxin is important in clinical decision making:

Botulinum Toxin Types Comparison Table (BoNT/A Products)

feature	botox	Dysport	Xeomin	jeuveau	Daxxify
Generic Name	Onabotulinumtoxin-A	Abobotulinumtoxin-A	Incobotulinumtoxin-A	Prabotulinumtoxin-A	Dabotulinumtoxin-A
Manufacturer	Allergan (AbbVie)	ipsen	Merz Pharmaceuticals	Daewoong (Evolus market)	Revance Therapeutics
FDA Approval Date (Cosmetics)	2002	2009	2011	May 2019	September 2023
Onset of Effect	4-7 days	2-3 days (fast)	5-7 days	2-3 days (fast)	1-2 days (fastest)
Effect Duration	3-6 months (avg 4 months)	3-4 months	3-4 months	3-4 months	6-9 months (longest)
Unit Equivalence	Baseline (1 = 1)	1 Botox = 2.5-3 Dysport	1 Botox = 1 Xeomin	1 Botox = 1 Jeuveau	1 Botox = 1 Daxxify
Accessory Proteins	Yes (complex)	Yes (complex)	NONE (naked toxin)	Yes (complex)	Yes (peptide-conjugated)
Diffusion Profile	Narrow	broad	Narrow	Medium	Narrow
Immunogenicity Risk	Low-Medium	Low-Medium	lowest (naked)	Medium (complex)	Low (peptide-bound)
Price (US Market, avg)	baseline	similar to botox	similar to botox	20-30% lower than Botox	Premium (long effect)
Market Position	Gold standard leader	Rapid-onset alternative	Hypoallergenic alternative	Economy + rapid-onset	Long-duration premium
Türkiye TITCK Approval	✓ Yes	✓ Yes	✓ Yes	✗ No	✗ No (new)

Comparison Notes:

• Jeuveau vs Botox: Jeuveau has a dose equivalent to Botox, but differs with its rapid onset of effect (2-3 days vs 4-7 days) and economical pricing. Containing accessory protein, it has more immunogenic potential than Xeomin; However, in clinical practice, antibody development is rare with both products.
• Jeuveau vs Dysport: Both show a rapid onset of effect within 2-3 days. Dysport is known for wider diffusion (broader spreading); Jeuveau exhibits a medium diffusion profile. Dosage calculation is simpler with Dysport 1:2.5-3 while Jeuveau 1:1 vs Botox.
• Jeuveau vs Xeomin: Xeomin is a "naked toxin" and carries the lowest immunogenicity risk; Jeuveau contains accessory protein. Jeuveau's rapid onset of action (2-3 days) is an advantage over Xeomin (5-7 days). The price is higher than Xeomin.
• Jeuveau vs Daxxify: Daxxify is the newest (2023 FDA approval), longest duration of effect (6-9 months), fastest onset (1-2 days). Jeuveau, for the patient profile targeting economical and rapid onset; Daxxify is for the patient who wants long-duration and premium positioning. The price is the highest in Daxxify.

Side Effects and Contraindications

Local Side Effects (Common):

• Injection Site Reactions: Local pain, erythema (redness), swelling — typically resolve within 1-3 hours, maximally within 24 hours. In/English: bruising (ecchymosis), especially more common in anticoagulant or aspirin users.
• Ptosis (Eyelid Droop): Complication occurring with incorrect injection (superficial or lateral) and spread to the levator palpebrae superior muscle, observed with a frequency of <1%. Self-limited, recovery is expected within 2-3 weeks. Apraclonidine drops may provide symptomatic relief.
• Asymmetrical Eyebrow Position ("Spock Eyebrow"): Asymmetric dose distribution, frontalis vs corrugator balanced targeting result. Conservative approach (time + touch-up dilute injection) is recommended.
• Hematoma (bruising): Capillary damage, during or after injection. More common in patients using anticoagulants (warfarin) or antiplatelets (aspirin). Hemostasis (local pressure) and post silicone based powder / arnica topical first aid.

Systemic / Rare Side Effects:

• Headache: 1-10% frequency. It may be caused by injection trauma or the activity of the toxin on the nerve environment in the relevant area. NSAID (paracetamol, ibuprofen) responsive, resolve within 24-48 hours.
• Blowing/Fluu-like Symptoms: Rare (<1%), viral-like prodrome. Self-limited, supportive care.
• Angioedema and Anaphylaxis: Very rarely, patients with high allergy predisposition are in the risk group. Emergency adrenaline (epinephrine) and antihistamine should be available.
• Urticaria (Allergic Skin Reaction): Allergy to excipients in the Jeuveau formulation (albumin, gelatin) or to the toxin itself. Antihistamine or steroid cream treatment.

Contraindications (Absolute and Relative):

• Absolute Contraindications:
  • Pregnancy and breast-feeding (category C)—insufficient safety data; absolute contraindication.
  • Known botulinum toxin allergy — hypersensitivity past reaction.
  • Neuromuscular diseases: Myasthenia gravis, Lambert-Eaton syndrome, ALS — may increase the effect of the toxin at the neuromuscular junction, risk of severe systemic paralysis.
  • Active infection (at the injection site): Cellulitis, acne, acne, etc.
• Relative Contraindications (Apply with Caution):
  • Aminoglycoside antibiotics (gentamicin, tobramycin, amikacin) — may increase the risk of complications by potentiating the neuromuscular blocking effect of the toxin.
  • Anticoagulant (warfarin, apixaban) or antiplatelet (aspirin, clopidogrel) — increased risk of bruising.
  • Bleeding disorder (hemophilia, von Willebrand disease) — risk of ecchymosis and hematoma.
  • Patients with unrealistic expectations or mental health problems — risk of iatrogenic disorders (body dysmorphic disorder, obsessive-compulsive injections).

Duration of Effect and Adherence to Retreatment

Impact Timeline: Expected timeline after Jeuveau glabellar injection:

• 0-2 days (Onset Window): Minimal impact. In the first 24 hours, mild loosening may begin at the injection site; but most patients do not notice.
• 3-7 days (Active Improvement Period): Progressive effect. Patients report a reduction in frown lines and visible softening of glabellar lines. Weekly progress can be documented with photographs.
• 2-3 weeks (Peak Effect): Maximal motor blockade is reached. Corrugator contractility is reduced by 70-80%. Dynamic lines are minimal, static lines improve without fillers.
• 3-4 months (Plateau): The effect remains stable. Patients report that after starting at intervals of 3-4 months, the effect will begin to fade.
• 4-6 months (Fade): Nerve endings begin to synthesize new SNARE proteins, motor activity begins to return. Dynamic lines reappear.
• 6+ months (Baseline Return): Many patients return to baseline (pre-injection) muscle activity after 6 months. Repeat injection, 12-13. It renews around the week.

Adherence to Retreatment (Habituation Risk): Repeated injections of Jeuveau (and other BoNT/A products) carry the risk of development of neutralizing antibodies. This "antibody development" or "non-responder state" is observed with a frequency of approximately 1-5% of:

• Repeated injections (>3-5 times, especially at short intervals)
• High dose injections (100U+ total per session)
• Frequent retreatment (<3 months apart)

In case of antibody development, the response to the same product (Jeuveau) may be lost. Many clinicians use a brand switching strategy (e.g. Jeuveau → Xeomin “naked”). Since Xeomin does not contain accessory protein, it has lower immunogenicity.

Antibody Development and Resistance Mechanism

Neutralizing Antibody (NAb) Formation: Jeuveau has the potential for antibody development compared to Xeomin because it contains accessory proteins. The mechanism of immunology is as follows:

• Complex accessory proteins of the toxin can be visualized as non-self proteins.
• B-lymphocytes produce IgG and IgM neutralizing antibodies (NAbs) against the toxin.
• In subsequent injections, NAbs passively neutralize the toxin, blocking it before it reaches the neuromuscular junction.
• From the clinician's perspective, a "non-responder" situation: loss of effect despite increasing dose.

Strategies to Minimize Antibody Development:

• Dose Titration: Use minimal effective dose. Unnecessary dose increase increases immunogenic burden.
• Retreatment Intervals: 3-4 months minimum interval hair; <3 months retreatment is risky.
• Brand Alternation: Switching from Jeuveau to Xeomin (naked toxin) or vice versa may reduce antibody cross-reactivity.
• Therapeutic "Holiday": In rare cases, not giving Jeuveau for 12 months (to eliminate antibody titers); However, patients may not prefer this.

Treatment in Case of Development of Resistance:

• If there is no response to the same product (Jeuveau), a higher dose may provide temporary benefit; but the root cause (antibody) is not resolved.
• Brand switching (Xeomin, Daxxify, Dysport) can be tried; Xeomin is used by many with success.
• Surgical alternative (corrugator myectomy, neurectomy) — permanent solution, but invasive.
• Hyaluronidase pretreatment—additional research is being done to see if this may reduce antibody development.

Situation and Market Analysis in Türkiye

TITCK Approval: Jeuveau (prabotulinumtoxin-A) is not approved by TITCK (Turkish Medicines and Medical Devices Agency) in Türkiye. This means that Jeuveau cannot be legally sold or prescribed in Türkiye. Botulinum toxin products legally used in Türkiye: Botox (Allergan/AbbVie), Dysport (Ipsen), Xeomin (Merz) — all three are TITCK approved.

Türkiye Market Characteristic:

• Market Leader: Botox is dominant in the Turkish aesthetic market with a market share of 60-70% (estimated). Dysport holds the second position (20-25%), while Xeomin holds the small niche share (5-10%).
• Price Dynamics: In Türkiye, Botox and Dysport compete on price; Botox is generally priced higher, Dysport mid-range, Xeomin premium.
• Jeuveau Reality: Jeuveau is not legally stocked in Turkish clinics due to the lack of TITCK approval. However, in some tourism-driven regions (especially Istanbul, Ankara private clinics) discourses of imported and "conditional" use can be heard; This is a legal gray area.

Jeuveau's popularity in Türkiye: Jeuveau is relevant in the Turkish context for two main segments:

1. Information of Patients in International Tourism: Turkish tourists may encounter Jeuveau for aesthetic treatment in Dubai, Europe, USA; can ask for relevant information and make price-performance comparisons. Most of them prefer Botox/Dysport treatment on their return to Türkiye (for legal security reasons).
2. Approval Process Tracking: Turkish aesthetic clinicians follow international market trends. Jeuveau's FDA approval in 2019 and Daxxify's 2023 approval create international consensus; This could be the catalyst for Türkiye TITCK approval files. In the future, Evolus or distributors may apply for TITCK approval.

Related Terms and Cross-References

• Botox (Onabotulinumtoxin-A) — Jeuveau's main benchmark brand, unit equivalence 1:1, FDA approval 2002.
• Dysport (Abobotulinumtoxin-A) — Jeuveau's rapid-onset peer, but dose conversion 1:2.5-3.
• Xeomin (Incobotulinumtoxin-A) — "Naked toxin" alternative, lower antibody development, more immunocompatible than Jeuveau.
• Daxxify (Dabotulinumtoxin-A) — Newest botulinum toxin, 6-9 months effect, longer than Jeuveau.
• Forehead Botox (Glabellar Botox) — Jeuveau's primary indication, protocol and technique are the same.
• Botulinum Toxin Types (BoNT/A, BoNT/B, etc.) — Context of Jeuveau's BoNT/A type classification.
• Masseter Botox (Off-Label) — Jeuveau off-label usage example.
• Neuromuscular Junction (NMJ) — Jeuveau's mechanism of action.

Frequently Asked Questions

1. What is Jeuveau, how is it different from Botox?

   Jeuveau is a prabotulinumtoxin-A product manufactured by Daewoong, marketed by Evolus. The main differences of Jeuveau from Botox: (1) Fast onset of effect (2-3 days vs Botox 4-7 days), (2) Equivalent dose (1:1 unit equivalence, different from Dysport), (3) More economical price (20-30% cheaper than Botox), (4) Cosmetic-only FDA approval (no medical indication), (5) No TITCK approval in Türkiye (Botox yes). The mechanism is the same: BoNT/A, SNAP-25 stimulation, neuromuscular block.

2. How long does the Jeuveau effect last?

   The onset of Jeuveau effect occurs in 2-3 days (rapid), and the maximum effect occurs after 2-3 weeks. The duration of effect is 3-4 months (average 4 months). The effect begins to fade after 4-6 months and most patients prefer repeat injections every 12-13 weeks (3-4 months). Like Botox, the duration of effect may vary depending on factors such as patient anatomy, dose, metabolism (range 3-6 months).

3. Can Jeuveau be used in Türkiye?

   No, since Jeuveau does not have TITCK approval in Türkiye, it cannot be officially sold or prescribed. Legal botulinum toxin products in Türkiye: Botox, Dysport, Xeomin. However, even if a clinician imports from abroad, this is a legal gray area and insurance coverage. Jeuveau's approval in Türkiye is limited to patients' knowledge and the possibility of future TITCK approval in foreign tourism.

4. Why is Jeuveau price lower than others?

   Jeuveau was positioned as "economy botulinum toxin" by Evolus' strategic marketing decision. Daewoong's Korean manufacturing efficiency and Evolus' lower margin targeting have allowed for a 20-30% lower price than Botox and Dysport. However, the efficacy and safety profile is equivalent to Botox; The price difference is due to brand value and patent/market positioning power.

5. What does Jeuveau "Newtox" mean?

   "Newtox" is Evolus' marketing tagline for Jeuveau: "New" + "toxin". "Newtox" brand positioning emphasizes the meaning of "new generation botulinum toxin, cosmetic-focused, rapid-onset, economical". This is a strategy to specifically target younger, cosmetic-seeking patients, rather than a medical-focused profile like Botox or a broad-diffusion profile like Dysport.

6. Does Jeuveau work faster than Botox?

   Yes, Jeuveau's onset of action is 2-3 days, Botox's 4-7 days. It exhibits a similar rapid-onset profile as Jeuveau's Dysport. This is because Jeuveau's diffusion and uptake profile provides Dysport-like rapid neuromuscular junction access. However, after 2-3 weeks, both products reach their maximal effect and the post-effect duration is similar (3-4 months).

7. Is there a risk of developing antibodies from Jeuveau?

   Yes, there is risk. Jeuveau contains accessory proteins and is complex; This is more immunogenic potential than Xeomin. Antibody (neutralizing antibody) may develop with repeated injections, especially with short intervals (<3 months) and high doses (100U+). Clinical frequency is in the range of 1-5%. In the case of antibodies, brand switching (such as Xeomin) is applied.

8. What are the side effects of Jeuveau?

   Jeuveau side effects are minimal and temporary, like Botox. Frequent local effects: local pain, erythema, swelling (1-3 hours). Rare ptosis (<1%, incorrect injection). Headache (1-10%). Systemic side effects are rare. Contraindications: pregnancy, myasthenia gravis, active infection, known allergy. Aminoglycoside antibiotics and anticoagulants with caution.

9. How many days does it take to see the full effect of Jeuveau?

   The onset of Jeuveau effect begins within 2-3 days; However, the "full" (maximal) effect occurs after 2-3 weeks. Most patients report visible improvement after 1-2 weeks, with motor block completeness reaching its peak level by the 3rd week. Recommendation: impact evaluation after 2 weeks; If more effect is required, touch-up can be done after 2-4 weeks.

10. How to adjust the dosage of Jeuveau in men?

    In men, since the corrugator muscle is denser and has greater mass, 40-50U of Jeuveau is injected instead of the standard glabellar dose of 20-40U. For women, a more moderate dose of 20-30U can provide effective results while preserving natural brow. Male specification results from grooming habits (aggressive frowning) and testosterone-driven muscle hypertrophy.

11. Jeuveau vs Daxxify: which should be preferred?

    Jeuveau: rapid onset (2-3 days), medium duration of action (3-4 months), economical price — if patients prefer frequent injections or want fast results. Daxxify: fastest onset (1-2 days), longest effect (6-9 months), premium price — if patients prefer less frequent injections or want long-duration. The selection is made based on patient expectation, lifestyle, budget and clinic preference.

12. Where is the source of Jeuveau product?

    Jeuveau is manufactured by Daewoong Pharmaceutical (South Korea) and Evolus Inc. Marketed by (USA). Daewoong is known for manufacturing most medical products in South Korea. Jeuveau is manufactured in accordance with global standards (GMP, FDA cGMP) and has production certification in an FDA-approved facility.

Op. Dr. Hamza Gemici Comment

Jeuveau gained rapid market share in the global botulinum toxin market following the 2019 FDA approval. It has become popular especially in the USA and high-volume aesthetic clinics, with its economical positioning and rapid-onset profile. From the plastic surgeon's perspective, the Jeuveau mechanism is completely equivalent to Botox, and its 1:1 unit equivalence structure simplifies dose calculations.

In our clinic (hamzagemici.com), in the Turkish context, we do not apply Jeuveau directly because it is not legally approved; However, in international consultations, we respond to Jeuveau inquiries of patients examined in foreign tourism. Jeuveau's rapid-onset advantage (2-3 days) is attractive for patients who want quick results before particular events (weddings, conferences).

Antibody development (non-responder state) can be observed in long-term Jeuveau users; In this case, I recommend the brand switching (Xeomin) strategy. In terms of price-performance, Jeuveau is ideal for entry-level cosmetic patients; However, it is important to offer alternative options to patients who want premium results and long-duration (such as Daxxify).

Botox, Dysport, Xeomin, Jeuveau, Daxxify — five botulinum toxin products, with a variety of onset, duration, diffusion profiles and price points, provide the clinician with a patient-customized approach. Each product delivers optimal results to a specific patient demographic.

Resources

1. Evolus Inc. Jeuveau (prabotulinumtoxin-A) FDA Prescribing Information. https://www.jeuveau.com/. FDA Approval May 2019.
2. FDA. Jeuveau (prabotulinumtoxin-A) BLA Approval Letter. Center for Drug Evaluation and Research. May 2019. https://www.fda.gov/drugs/
3. Sattler G, Callander M, Levy P, et al. Efficacy and Safety of a new Botulinum Toxin Type A (Prabotulinumtoxin-A) in the treatment of Glabellar Frown Lines in Adults: A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial. Dermatol Surg. 2020;46(4):513-522. doi:10.1097/DSS.0000000000002070.
4. Park KH, Oh MR, Kang SH, et al. A randomized, double-blind, placebo-controlled trial of a novel botulinum toxin A (DWP450) on the treatment of glabellar lines. J Cosmet Dermatol. 2021;20(3):848-854. doi:10.1111/jocd.13577.
5. Ramirez OM, Rohaizak M, Das JM. Botulinum Toxin: A Comprehensive Review of its Role in Medical and Aesthetic Practice. Plast Reconstr Surg Glob Open. 2021;9(3):e3518. doi:10.1097/GOX.0000000000003518.
6. Roggenkamper P, Jost WH, Bihari K, et al. Efficacy and Safety of a New Botulinum Toxin Type A Free of Complexing Proteins in the treatment of Blepharospasm. J Neural Transm (Vienna). 2006;113(3):303-312. doi:10.1007/s00702-005-0321-5. [Xeomin comparative context]
7. Allergan Inc. Botox (onabotulinumtoxinA) FDA Prescribing Information. https://www.botoxcosmetic.com/. FDA Approval 2002.
8. Ipsen. Dysport (abobotulinumtoxinA) FDA Prescribing Information. https://www.dysportusa.com/. FDA Approval 2009.
9. Merz Pharmaceuticals. Xeomin (incobotulinumtoxinA) FDA Prescribing Information. https://www.xeomin.com/. FDA Approval 2011.
10. Carruthers J, Fagien S, Matarasso SL, et al. Consensus Recommendations on the Use of Botulinum Toxin Type A in Facial Aesthetics. Plast Reconstr Surg. 2004;114(6 Suppl):1S-22S. PMID: 15371835.

Last Update

Last update: April 22, 2026 · Medical editor: Op. Dr. Hamza Gemici